This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Debs, R J
Right arrow Articles by Papahadjopoulos, D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Debs, R J
Right arrow Articles by Papahadjopoulos, D

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1987 January; 31(1): 37-41

Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats.

R J Debs, W Blumenfeld, E N Brunette, R M Straubinger, A B Montgomery, E Lin, N Agabian and D Papahadjopoulos

ABSTRACT

We examined both the therapeutic efficacy and tissue distribution of aerosolized pentamidine in immunosuppressed rats with Pneumocystis carinii pneumonia. In rats immunosuppressed by 5 weeks of pretreatment with dexamethasone, a 2-week course of 5 mg of aerosolized pentamidine per kg per day, administered free or encapsulated in the drug carrier system (liposomes), eradicated P. carinii pneumonia in 75% of treated animals. At this dose, extrapulmonary drug uptake as measured by a sensitive high-pressure liquid chromatography assay was negligible. No significant differences in tissue distribution were noted between aerosolized free and liposome-encapsulated pentamidine. In rats receiving dexamethasone for 6 weeks prior to treatment with pentamidine, both lung uptake and therapeutic efficacy of aerosolized pentamidine (5 mg/kg per day) were substantially reduced. Aerosolized pentamidine appears to be an effective therapy for P. carinii pneumonia in rats and produces significantly lower extrapulmonary drug deposition than parenteral administration. The severity of P. carinii involvement at the time of treatment influences both the level of drug delivery to the lung and the response to aerosolized pentamidine therapy.

Antimicrob Agents Chemother. 1987 January; 31(1): 37-41




This article has been cited by other articles:

  • Pillai, R. S., Yeates, D. B., Miller, I. F., Hickey, A. J. (1998). Controlled dissolution from wax-coated aerosol particles in canine lungs. J. Appl. Physiol. 84: 717-725 [Abstract] [Full Text]  
  • Park, S., Wunderlich, H., Goldenberg, R. A., Marshall, M. (1992). Pneumocystis carinii Infection in the Middle Ear. Arch Otolaryngol Head Neck Surg 118: 269-270 [Abstract]  
  • Baskin, M. I., Abd, A. G., Ilowite, J. S. (1990). Regional Deposition of Aerosolized Pentamidine: Effects of Body Position and Breathing Pattern. ANN INTERN MED 113: 677-683 [Abstract]  
  • Soo Hoo, G. W., Mohsenifar, Z., Meyer, R. D. (1990). Inhaled or Intravenous Pentamidine Therapy for Pneumocystis carinii Pneumonia in AIDS: A Randomized Trial. ANN INTERN MED 113: 195-202 [Abstract]  
  • (1990). Questions and Answers. JAMA 263: 2510-2514  
  • Armstrong, D., Bernard, E. (1988). Aerosol Pentamidine. ANN INTERN MED 109: 852-854 [Abstract]  
  • CONTE, J. E. Jr., HOLLANDER, H., GOLDEN, J. A. (1987). Inhaled or Reduced-Dose Intravenous Pentamidine for Pneumocystis carinii Pneumonia: A Pilot Study. ANN INTERN MED 107: 495-498 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»